Thus, as the SLC1A5 variant is the only currently known glutamine transporter in the mitochondrial inner membrane16, targeting the SLC1A5 variant could be an effective strategy for selectively inhibiting glutamine metabolism in cancer cells (Fig. 8). This evidence concerns the gene SLC1A5 and cancer.